Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-03-16 00:00:00 ET · period of report 2025-12-02 · accession 0002048497-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-16 | 2025-12-02+ | BBNX | Hopman Mark | Chief Commercial Off | S - Sale | $30.27 | -2,917 | 136.2K | -2% | -$88.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-02 | S | D | 856 | $29.34 | 138,277 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-04 | S | D | 2,061 | $30.66 | 136,216 | D | — | — | (F3) The weighted average sale price for the transaction reported was $30.6610 and the range of prices were between $30.02 and $31.0024. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |